Determination of mesothelin levels in pleural effusion does not help predict survival of patients with malignant pleural mesothelioma

Vincenzo Fontana, Maria P.I.A. Pistillo, Antonella Vigani, Pier Aldo Canessa, Giovanni Berisso, Ugo Giannoni, Paola Ferro, Maria Cristiana Franceschini, Roberta Carosio, Marika Tonarelli, Cristiana Rossi, Paolo Dessanti, Silvio Roncella

Research output: Contribution to journalArticle

Abstract

Aim: This study evaluated the prognostic value of soluble mesothelin-related protein (SMRP) levels in pleural effusions (PE) from patients with pleural mesothelioma (MPM). Patients and Methods: SMRP level in PE was tested using an enzyme-linked immunosorbent assay (ELISA) in 109 patients with MPM at diagnosis before any treatment. The Kaplan–Meier method and the Cox regression were applied to compare overall survival probabilities across tertile categories of SMRP level. Results: No significant differences in Kaplan–Meier overall survival probabilities among the SMRP categories were found. A statistically non-significant trend for increased death rate ratio (RR) was computed (p=0.327) when the higher (>46.5 nM, RR=1.38) and intermediate (8.5-46.5 nM, RR=1.18) SMRP categories were compared to the lower category (<8.5 nM, RR=1.00). Cox regression modelling including a restricted cubic spline showed a moderately rising non-linear trend in death rate. Conclusion: The SMRP level in PE does not appear to have prognostic significance and its detection is not recommended in routine clinical management of patients with MPM.

Original languageEnglish
Pages (from-to)5219-5223
Number of pages5
JournalAnticancer Research
Volume39
Issue number9
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Pleural Effusion
Survival
Proteins
Mortality
Mesothelioma
Malignant Mesothelioma
mesothelin
Enzyme-Linked Immunosorbent Assay

Keywords

  • Mesothelin
  • Mesothelioma
  • Pleural effusion
  • Prognosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Determination of mesothelin levels in pleural effusion does not help predict survival of patients with malignant pleural mesothelioma. / Fontana, Vincenzo; Pistillo, Maria P.I.A.; Vigani, Antonella; Canessa, Pier Aldo; Berisso, Giovanni; Giannoni, Ugo; Ferro, Paola; Franceschini, Maria Cristiana; Carosio, Roberta; Tonarelli, Marika; Rossi, Cristiana; Dessanti, Paolo; Roncella, Silvio.

In: Anticancer Research, Vol. 39, No. 9, 01.01.2019, p. 5219-5223.

Research output: Contribution to journalArticle

Fontana, V, Pistillo, MPIA, Vigani, A, Canessa, PA, Berisso, G, Giannoni, U, Ferro, P, Franceschini, MC, Carosio, R, Tonarelli, M, Rossi, C, Dessanti, P & Roncella, S 2019, 'Determination of mesothelin levels in pleural effusion does not help predict survival of patients with malignant pleural mesothelioma', Anticancer Research, vol. 39, no. 9, pp. 5219-5223. https://doi.org/10.21873/anticanres.13719
Fontana, Vincenzo ; Pistillo, Maria P.I.A. ; Vigani, Antonella ; Canessa, Pier Aldo ; Berisso, Giovanni ; Giannoni, Ugo ; Ferro, Paola ; Franceschini, Maria Cristiana ; Carosio, Roberta ; Tonarelli, Marika ; Rossi, Cristiana ; Dessanti, Paolo ; Roncella, Silvio. / Determination of mesothelin levels in pleural effusion does not help predict survival of patients with malignant pleural mesothelioma. In: Anticancer Research. 2019 ; Vol. 39, No. 9. pp. 5219-5223.
@article{c6b1a04265cf44eb876fd5c25dfda638,
title = "Determination of mesothelin levels in pleural effusion does not help predict survival of patients with malignant pleural mesothelioma",
abstract = "Aim: This study evaluated the prognostic value of soluble mesothelin-related protein (SMRP) levels in pleural effusions (PE) from patients with pleural mesothelioma (MPM). Patients and Methods: SMRP level in PE was tested using an enzyme-linked immunosorbent assay (ELISA) in 109 patients with MPM at diagnosis before any treatment. The Kaplan–Meier method and the Cox regression were applied to compare overall survival probabilities across tertile categories of SMRP level. Results: No significant differences in Kaplan–Meier overall survival probabilities among the SMRP categories were found. A statistically non-significant trend for increased death rate ratio (RR) was computed (p=0.327) when the higher (>46.5 nM, RR=1.38) and intermediate (8.5-46.5 nM, RR=1.18) SMRP categories were compared to the lower category (<8.5 nM, RR=1.00). Cox regression modelling including a restricted cubic spline showed a moderately rising non-linear trend in death rate. Conclusion: The SMRP level in PE does not appear to have prognostic significance and its detection is not recommended in routine clinical management of patients with MPM.",
keywords = "Mesothelin, Mesothelioma, Pleural effusion, Prognosis",
author = "Vincenzo Fontana and Pistillo, {Maria P.I.A.} and Antonella Vigani and Canessa, {Pier Aldo} and Giovanni Berisso and Ugo Giannoni and Paola Ferro and Franceschini, {Maria Cristiana} and Roberta Carosio and Marika Tonarelli and Cristiana Rossi and Paolo Dessanti and Silvio Roncella",
year = "2019",
month = "1",
day = "1",
doi = "10.21873/anticanres.13719",
language = "English",
volume = "39",
pages = "5219--5223",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "9",

}

TY - JOUR

T1 - Determination of mesothelin levels in pleural effusion does not help predict survival of patients with malignant pleural mesothelioma

AU - Fontana, Vincenzo

AU - Pistillo, Maria P.I.A.

AU - Vigani, Antonella

AU - Canessa, Pier Aldo

AU - Berisso, Giovanni

AU - Giannoni, Ugo

AU - Ferro, Paola

AU - Franceschini, Maria Cristiana

AU - Carosio, Roberta

AU - Tonarelli, Marika

AU - Rossi, Cristiana

AU - Dessanti, Paolo

AU - Roncella, Silvio

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Aim: This study evaluated the prognostic value of soluble mesothelin-related protein (SMRP) levels in pleural effusions (PE) from patients with pleural mesothelioma (MPM). Patients and Methods: SMRP level in PE was tested using an enzyme-linked immunosorbent assay (ELISA) in 109 patients with MPM at diagnosis before any treatment. The Kaplan–Meier method and the Cox regression were applied to compare overall survival probabilities across tertile categories of SMRP level. Results: No significant differences in Kaplan–Meier overall survival probabilities among the SMRP categories were found. A statistically non-significant trend for increased death rate ratio (RR) was computed (p=0.327) when the higher (>46.5 nM, RR=1.38) and intermediate (8.5-46.5 nM, RR=1.18) SMRP categories were compared to the lower category (<8.5 nM, RR=1.00). Cox regression modelling including a restricted cubic spline showed a moderately rising non-linear trend in death rate. Conclusion: The SMRP level in PE does not appear to have prognostic significance and its detection is not recommended in routine clinical management of patients with MPM.

AB - Aim: This study evaluated the prognostic value of soluble mesothelin-related protein (SMRP) levels in pleural effusions (PE) from patients with pleural mesothelioma (MPM). Patients and Methods: SMRP level in PE was tested using an enzyme-linked immunosorbent assay (ELISA) in 109 patients with MPM at diagnosis before any treatment. The Kaplan–Meier method and the Cox regression were applied to compare overall survival probabilities across tertile categories of SMRP level. Results: No significant differences in Kaplan–Meier overall survival probabilities among the SMRP categories were found. A statistically non-significant trend for increased death rate ratio (RR) was computed (p=0.327) when the higher (>46.5 nM, RR=1.38) and intermediate (8.5-46.5 nM, RR=1.18) SMRP categories were compared to the lower category (<8.5 nM, RR=1.00). Cox regression modelling including a restricted cubic spline showed a moderately rising non-linear trend in death rate. Conclusion: The SMRP level in PE does not appear to have prognostic significance and its detection is not recommended in routine clinical management of patients with MPM.

KW - Mesothelin

KW - Mesothelioma

KW - Pleural effusion

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=85072208678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072208678&partnerID=8YFLogxK

U2 - 10.21873/anticanres.13719

DO - 10.21873/anticanres.13719

M3 - Article

VL - 39

SP - 5219

EP - 5223

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 9

ER -